Therapeutic Action
Sedating H1 antihistamine
Source page 484
Loading InternPractice…
Individual generic drug information
Extracted information for PROMETHAZINE only.
Sedating H1 antihistamine
Source page 484
Agitation or aggressive behaviour in patients with acute or chronic psychosis, in combination with haloperidol
Source page 484
Extracted information for PROMETHAZINE only.
Administer with caution and monitor use: in older patients; in patients with prostate disorders, closed-angle glaucoma, epilepsy, orthostatic hypotension, severe renal or hepatic impairment; in patients taking central nervous system depressants (opioid analgesics, antipsychotics, sedatives, antidepressants, etc.) or drugs known to have an anticholinergic effect (atropine, amitriptyline, chlorpromazine, etc.). May cause: drowsiness, dizziness, headache, confusional state, hypotension, photosensitivity (protect skin from sun exposure); anticholinergic effects (dry mouth, constipation, blurred vision, tachycardia, disorders of micturition); tissue damage, including necrosis; rarely: seizures, extrapyramidal syndrome, neuroleptic malignant syndrome (unexplained hyperthermia with neuromuscular disorders), allergic reactions. Pregnancy and breast-feeding: avoid
Source pages 484, 485
Extracted information for PROMETHAZINE only.
50 mg in 2 ml ampoule (25 mg/ml) for deep IM injection. NEVER ADMINISTER BY SC INJECTION.
Source page 484
Adult: 25 mg, to be repeated after 30 minutes if necessary. If no response 30 minutes after the second dose, administer 50 mg (total dose max. 100 mg).
Source page 484
Extracted information for PROMETHAZINE only.
Promethazine by IV route should only be used in intensive care unit, at a max. concentration of 1 mg/ml by infusion over 20 minutes using a central catheter or a large bore peripheral catheter (risk of necrosis and peripheral gangrene). Promethazine is not included in the WHO list of essential medicines.
Source page 485
– Below 25 °C
Source page 485
Filter the extracted dose blocks for this individual drug.
25 mg, to be repeated after 30 minutes if necessary. If no response 30 minutes after the second dose, administer 50 mg (total dose max. 100 mg).
Candidate age grouping · source page 484